{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:15:10Z","timestamp":1782893710491,"version":"3.54.5"},"reference-count":48,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,2,25]],"date-time":"2011-02-25T00:00:00Z","timestamp":1298592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Accurate data about childhood acute lymphoblastic leukemia (ALL) in low\u2010 and middle\u2010income countries are lacking. Our study is designed to assess survival of childhood ALL at King Hussein Cancer Center (KHCC) using modified St. Jude Children's Research Hospital protocols.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We reviewed the medical records of children 1\u201318 years of age who were diagnosed with ALL and treated at KHCC from January 2003 through December 2009. Disease characteristics and outcome were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over a 7\u2010year period, 300 children with ALL were treated. One hundred and seventy\u2010three (57.7%) were males and 127 (42.3%) were females. The median age at diagnosis was 5 years. One hundred and fifty\u2010seven (52.3%) children were classified as low\u2010risk, 118 (39.3%) were standard\u2010risk and 25 (8.3%) were high\u2010risk. Two hundred and sixty\u2010two (88.5%) children had pre\u2010B cell phenotype and 34 (11.5%) had T\u2010cell phenotype. Two hundred and seventy\u2010three (91.3%) children were classified as having CNS I disease, 24 (8%) had CNS II, and 2 (0.67%) had CNS III. Cytogenetic abnormalities included: t(12;21) in 30 (12%) children and t(9;22) in 18 (7.4%). Four (1.3%) children died in induction, 6 (2%) died in first remission and 27 (9%) relapsed. After a median follow\u2010up of 34.5 months (range 0.32\u201384.5), the estimated 5\u2010year event free survival and overall survival were 80% and 89%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment protocols developed by major cooperative groups and institutions to treat childhood ALL was successfully adapted and suggest that such an approach may be useful in other low\u2010 and middle\u2010income countries. Pediatr Blood Cancer 2011; 57: 385\u2013391. \u00a9 2011 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.23065","type":"journal-article","created":{"date-parts":[[2011,2,26]],"date-time":"2011-02-26T16:05:51Z","timestamp":1298736351000},"page":"385-391","source":"Crossref","is-referenced-by-count":34,"title":["Outcome of childhood acute lymphoblastic leukemia in Jordan"],"prefix":"10.1002","volume":"57","author":[{"given":"Hadeel","family":"Halalsheh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najyah","family":"Abuirmeileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawad","family":"Rihani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiha","family":"Bazzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Zaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"Madanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200001000-00002"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.6397"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60457-2"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1616"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.251"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.096"},{"key":"e_1_2_5_11_2","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL\u2010BFM 90. German\u2010Austrian\u2010Swiss ALL\u2010BFM Study Group","volume":"95","author":"Schrappe M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421402"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07769.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05611.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705914"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70228-1"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66998-X"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2471"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31802d3e7a"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.248"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22127"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2008.251"},{"key":"e_1_2_5_23_2","first-page":"CR792","article-title":"An analysis of prognostic factors and the five\u2010year survival rate in childhood acute lymphoblastic leukemia","volume":"8","author":"Karimi M","year":"2002","journal-title":"Med Sci Monit"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70194-3"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023001"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386"},{"key":"e_1_2_5_27_2","first-page":"S124","article-title":"Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia","volume":"83","author":"Pui CH","year":"2004","journal-title":"Ann Hematol"},{"key":"e_1_2_5_28_2","unstructured":"HealthMo.Cancer incidence in Jordan. Jordan cancer registry booklet 2007. pp. 67\u201368."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32831f1f24"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008366814109"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199908)33:2<88::AID-MPO5>3.0.CO;2-Z"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.11.004"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/45.6.367"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.2870030102"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.4238\/vol8-1gmr582"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14241-9"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14228-6"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.9.2817"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.002"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0826-1"},{"key":"e_1_2_5_41_2","first-page":"735","article-title":"Biology and treatment of childhood T\u2010lineage acute lymphoblastic leukemia","volume":"91","author":"Uckun FM","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.12"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2950"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8934"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2691"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.4.1094"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22180"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22119"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23065","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.23065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T22:45:06Z","timestamp":1696891506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.23065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,25]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1002\/pbc.23065"],"URL":"https:\/\/doi.org\/10.1002\/pbc.23065","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,25]]}}}